Terrible shame. I wonder how it would have been if they actually continued the trial with larger numbers over longer time frames to get a more statistically significant result. Management has been very poor. Warning signs started with this last year when they halted the Phase III trial early. Thankfully been out for a while. I still reckon this would be a very useful addition to the the anti HIV arsenal but it looks to be down the gurgler. They now have the dubious distinction of being the first HIV med ever that has reached Phase III and failed to reach market!
AVX Price at posting:
2.9¢ Sentiment: None Disclosure: Not Held
